Used in research to inhibit DNA ligase IV, SCR7 Pyrazine is applied in studies involving non-homologous end joining (NHEJ), a pathway for DNA repair. It promotes gene editing efficiency by shifting repair toward homology-directed repair (HDR), making it valuable in CRISPR-Cas9 applications where precise genetic modifications are needed. It has also been explored in cancer research due to its potential to sensitize cells to radiation and DNA-damaging agents. However, its use remains primarily experimental, limited to in vitro and preclinical models.